| Torisel (temsirolimus) / Pfizer |
NCT00574483: Treatment of Advanced Renal Cell Carcinoma With Quinacrine |
|
|
| Withdrawn | 2 | 0 | US | quinacrine, CBLC102 | Cleveland BioLabs | Renal Cell Carcinoma | 01/08 | 01/08 | | |
NCT00494091: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma |
|
|
| Completed | 2 | 82 | Japan, RoW | Temsirolimus (CCI-779), Torisel | Pfizer | Advanced Renal Cell Carcinoma | 05/11 | 03/12 | | |
|
| Completed | 2 | 160 | Europe | Temsirolimus, Torisel®, Bevacizumab, Avastin®, Sunitinib, Sutent®, Interferon alpha-2a, Roféron® | Centre Leon Berard | Metastatic Renal Cell Carcinoma | 02/12 | 02/12 | | |
|
|
|
| Completed | 2 | 22 | Europe | Temsirolimus, Sunitinib | Central European Society for Anticancer Drug Research | Non-clear Cell Renal Cell Cancer | 07/12 | | | |
NCT00378703: Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer |
|
|
| Completed | 2 | 361 | US, RoW | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 | 02/14 | 03/17 | | |
|
| Terminated | 2 | 4 | Europe | Sorafenib, Nexavar | Centro di Riferimento Oncologico - Aviano | Metastatic Renal Cell Carcinoma | 09/14 | 09/15 | | |
NCT00782275: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma |
|
|
| Completed | 2 | 41 | US | bevacizumab, avastin, temsirolimus, torisel | Beth Israel Deaconess Medical Center, Genentech, Inc., Dana-Farber Cancer Institute, Brigham and Women's Hospital, Vanderbilt University Medical Center | Renal Cell Carcinoma, Kidney Cancer | 05/15 | 05/15 | | |
|
NCT00923845: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer |
|
|
| Completed | 2 | 25 | US | Pentostatin, Nipent, Sirolimus, Rapamune, Cyclophosphamide, Cytoxan, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest | National Cancer Institute (NCI) | Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome | 06/15 | 06/17 | | |
| Terminated | 2 | 39 | Europe | Bevacizumab, Temsirolimus | Hellenic Cooperative Oncology Group | Kidney Cancer | 07/15 | 07/15 | | |
NCT02122003: Second Line Sorafenib After Pazopanib in Patients With RCC |
|
|
| Terminated | 2 | 16 | Europe | Sorafenib, Nexavar | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Metastatic Renal Cell Carcinoma | 11/17 | 11/17 | | |
NCT00417677: A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma |
|
|
| Terminated | 1/2 | 124 | US | Combination of Temsirolimus and Sunitinib | Wyeth is now a wholly owned subsidiary of Pfizer | Renal Cell Carcinoma | | 05/07 | | |
CRUK-08/015, NCT01090466 / 2007-007615-82: Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium |
|
|
| Completed | 1/2 | 15 | Europe | cisplatin, gemcitabine hydrochloride, temsirolimus, pharmacological study | Cardiff University | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer | 01/10 | 03/16 | | |
